In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter study

[1]  K. Mertens,et al.  Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  H. V. van Doorn,et al.  Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in South-East Asia. , 2022, International journal of antimicrobial agents.

[3]  H. Giamarellou,et al.  Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients , 2022, Antibiotics.

[4]  In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece. , 2022, The new microbiologica.

[5]  S. Pournaras,et al.  Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece , 2022, Frontiers in Cellular and Infection Microbiology.

[6]  S. Joshi,et al.  Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review , 2021, Journal of applied microbiology.

[7]  D. Paterson,et al.  Antibiotics in the clinical pipeline in October 2019 , 2020, The Journal of Antibiotics.

[8]  K. Bush,et al.  Critical analysis of antibacterial agents in clinical development , 2020, Nature Reviews Microbiology.

[9]  V. Baka,et al.  Dissemination of International Clone II Acinetobacter baumannii Strains Coproducing OXA-23 Carbapenemase and 16S rRNA Methylase ArmA in Athens, Greece. , 2020, Microbial drug resistance.

[10]  I. Morrissey,et al.  In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017 , 2019, Antimicrobial Agents and Chemotherapy.

[11]  Evangelos I. Kritsotakis,et al.  Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. , 2019, The Journal of antimicrobial chemotherapy.

[12]  G. Poulakou,et al.  The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How , 2019, Front. Public Health.

[13]  M. Hackel,et al.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. , 2019, International journal of antimicrobial agents.

[14]  L. Rüttiger,et al.  Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use , 2019, Scientific Reports.

[15]  O. Ercan,et al.  In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii , 2019, The Journal of antimicrobial chemotherapy.

[16]  R. Bonomo,et al.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections , 2018, Antimicrobial Agents and Chemotherapy.

[17]  S. Pournaras,et al.  Changes in antimicrobial resistance of clinical isolates of Acinetobacter baumannii group isolated in Greece, 2010-2015. , 2018, Journal of medical microbiology.

[18]  G. Eliopoulos,et al.  Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model , 2018, Antimicrobial Agents and Chemotherapy.

[19]  D. Ehmann,et al.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii , 2017, Nature Microbiology.

[20]  A. Tsakris,et al.  Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. , 2017, International journal of antimicrobial agents.

[21]  G. Eliopoulos,et al.  Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. , 2017, Diagnostic microbiology and infectious disease.

[22]  K. Holt,et al.  Variants of AbGRI3 carrying the armA gene in extensively antibiotic-resistant Acinetobacter baumannii from Singapore , 2017, The Journal of antimicrobial chemotherapy.

[23]  P. Nordmann,et al.  Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. , 2015, International journal of antimicrobial agents.

[24]  D. Landman,et al.  Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City , 2014, Antimicrobial Agents and Chemotherapy.

[25]  M. Cooper,et al.  Antibiotics in the clinical pipeline in 2013 , 2013, The Journal of Antibiotics.

[26]  J. Xie,et al.  Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin , 2012, Proceedings of the National Academy of Sciences.

[27]  E. Petinaki,et al.  Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[28]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  S. Pournaras,et al.  Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). , 2011, The Journal of antimicrobial chemotherapy.

[30]  P. Visca,et al.  Acinetobacter infection – an emerging threat to human health , 2011, IUBMB life.

[31]  S. Brisse,et al.  Molecular Epidemiology of Multidrug-Resistant Acinetobacter baumannii in a Tertiary Care Hospital in Naples, Italy, Shows the Emergence of a Novel Epidemic Clone , 2010, Journal of Clinical Microbiology.

[32]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[33]  K. Towner,et al.  Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  M. Kaufmann,et al.  Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[35]  D. Yong,et al.  Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. , 2006, Diagnostic microbiology and infectious disease.

[36]  Antimicrobial Resistance in the EU/EEA , 2022 .

[37]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[38]  L. Peixe,et al.  OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro? , 2011, The Journal of antimicrobial chemotherapy.

[39]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[40]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .